This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Rosen Law Firm Announces Investigation Of Securities Claims Against Catalyst Pharmaceutical Partners, Inc.– CPRX

The Rosen Law Firm announces that it is investigating potential securities fraud claims against Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) resulting from allegations that the Company may have concealed that a competitor has been providing patients for free with a drug that is nearly biologically equivalent to the drug for which Catalyst seeks FDA approval

Catalyst is a development-stage company whose major product is Firdapse. Catalyst seeks FDA approval to sell Firdapse to treat Lambert-Eaton Myasthenic Syndrome ("LEMS"), a serious condition which only affects a few thousand people in the U.S.

But a competitor, Jacobus Pharmaceuticals, makes 3,4-DAP, a drug substantially equivalent to Firdapse. And on October 18, 2013, Adam Feuerstein (a journalist) revealed that Jacobus has been providing 3,4-DAP to patients, for free, pursuant to a number of compassionate use programs, for twenty years. That day, Catalyst's stock price fell from $2.61 to $1.90 on heavy volume, damaging investors.

The Rosen Law Firm is preparing a securities class action lawsuit on behalf of CPRX investors. If you purchased STSI stock before October 18, 2013, please visit the website at http://rosenlegal.com for more information. You may also contact Jonathan Horne, Esq., or Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at jhorne@rosenlegal.com or pkim@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs